HilleVax (NASDAQ:HLVX) Rating Increased to Hold at Wall Street Zen

Key Points

• HilleVax (NASDAQ:HLVX) was upgraded to a "hold" rating by Wall Street Zen and Zacks Research, reflecting a consensus price target of $2.00.
• The company's stock opened at $2.09 and has a market capitalization of $104.79 million with a 52-week price range between $1.34 and $2.17.
• HilleVax reported earnings of ($0.11) EPS for the last quarter, beating expectations, while analysts project an annual EPS of -2.64.

Wall Street Zen upgraded shares of HilleVax (NASDAQ:HLVX - Free Report) to a hold rating in a research note published on Saturday morning.

Separately, Zacks Research upgraded shares of HilleVax to a "hold" rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $2.00.

HilleVax Price Performance

Shares of NASDAQ HLVX remained flat at $2.09 during midday trading on Friday. HilleVax has a one year low of $1.34 and a one year high of $2.17. The business's 50-day simple moving average is $2.09 and its two-hundred day simple moving average is $1.92. The firm has a market cap of $104.79 million, a PE ratio of -1.46 and a beta of 0.77.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. On average, equities research analysts expect that HilleVax will post -2.64 earnings per share for the current fiscal year.

Institutional Trading of HilleVax

A number of institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC bought a new stake in HilleVax during the second quarter valued at $4,816,000. Deutsche Bank AG raised its holdings in shares of HilleVax by 32.9% during the fourth quarter. Deutsche Bank AG now owns 420,550 shares of the company's stock valued at $871,000 after purchasing an additional 104,001 shares during the period. Millennium Management LLC raised its holdings in shares of HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock valued at $852,000 after purchasing an additional 153,815 shares during the period. Trium Capital LLP acquired a new position in shares of HilleVax during the first quarter valued at about $548,000. Finally, Northern Trust Corp raised its holdings in shares of HilleVax by 2.8% during the fourth quarter. Northern Trust Corp now owns 249,610 shares of the company's stock valued at $517,000 after purchasing an additional 6,916 shares during the period. Institutional investors own 86.42% of the company's stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.